A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared with empagliflozin QD in Type-2-diabetes-mellitus patients with mild to moderate hypertension
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Sotagliflozin (Primary) ; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2019 Planned End Date changed from 7 Aug 2019 to 1 Apr 2019.